Asymmetric Complementarity: A Subtype-Specific Strategy via Visual Assessment of DCE-MRI and DWI for Evaluating NAT Efficacy in Breast Cancer.

Xiuyun Ge¹, Bin Zheng², Zhen Zhang², Jianle Liang², Wenjing Yuan², Jiarui Xie², Guanxun Cheng², Peng Sun³, Rong Huang⁴

¹Department of Medical Imaging, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China (X.G., B.Z., Z.Z., J.L., W.Y., J.X., G.C., R.H. ). Electronic address: gexiuyun@pkuszh.com.cn.

²Department of Medical Imaging, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China (X.G., B.Z., Z.Z., J.L., W.Y., J.X., G.C., R.H. ).

³Institute of Research and Clinical Innovations, Neusoft Medical Systems Co. Ltd, Shenyang, China (P.S.).

⁴Department of Medical Imaging, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China (X.G., B.Z., Z.Z., J.L., W.Y., J.X., G.C., R.H. ). Electronic address: r.huang@pkuszh.com.

PubMed DOI

Abstract

RATIONALE AND OBJECTIVES: To evaluate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging (DWI), based on clinical visual assessment for predicting pathological complete response (pCR) and measuring residual tumor size after neoadjuvant therapy (NAT) across breast cancer subtypes. MATERIALS AND METHODS: This retrospective study included 248 patients. Two…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.